) kicks off a busy week of earnings reports by banks. Investors are bracing for more bad news related to subprime loans and credit market turmoil. Wells Fargo (WFC
) results are due on Oct. 16, JPMorgan Chase (JPM
) and Washington Mutual (WM
) announce their numbers on Oct. 17, and Bank of America (BAC
) earnings come on Oct. 18.BERNANKE TALKSMon., Oct. 15, 9:15 a.m. EDTFederal Reserve Chairman Ben Bernanke speaks to the Economic Club of New York.BRITAIN'S ECONOMYTues., Oct. 16, 4:30 a.m. EDTSeptember inflation figures are released. Price pressures have abated this year. September retail sales and third-quarter economic growth data come on Oct. 18 and 19, respectively.EURO ZONE INFLATIONTues., Oct. 16, 5 a.m. EDTSeptember consumer price data will get a close look. Inflation is still a top concern for the European Central Bank, but signs of slower economic growth may keep the ECB on hold.BANK OF CANADATues., Oct. 16, 9 a.m. EDTEconomists expect the BOC to hold interest rates at 4.5%. Despite solid economic growth, a rising Canadian dollar has helped keep a lid on inflation.U.S. INDUSTRIAL OUTPUTTues., Oct. 16, 9:15 a.m. EDTIndustrial activity is expected to slow a bit further in September, after a soft 0.2% gain in August because of a large pullback in vehicle production.YAHOO! (YHOO
)Tues., Oct. 16, 5 p.m. EDTThe Internet giant presents third-quarter results. Share prices have surged more than 20% since late August.U.S. CONSUMER PRICESWed., Oct. 17, 8:30 a.m. EDTInflation probably rebounded in September on higher energy prices, after an August drop of 0.1%. Excluding food and energy, the index is expected to rise 0.2%.U.S. HOUSING STARTSWed., Oct. 17, 8:30 a.m. EDTMonthly housing starts in September probably slowed to an annual pace of 1.27 million, from a rate of 1.33 million.ALTRIA (MO
)Wed., Oct. 17, 12 p.m. EDTThe cigarette maker rolls out third-quarter earnings data after an 18% fall in profits last quarter.NOVARTIS (NVS
)Thurs., Oct. 18, 8 a.m. EDTInvestors await third-quarter results after the drugmaker reported that second-quarter profits jumped 18%. On Oct. 8 the Swiss company said that its Aclasta drug was approved in Europe to treat postmenopausal osteoporosis.